Corcept Therapeutics (CORT) Peer Comparison
$77.14
As on 04-Nov-2026 15:39EST
Market cap
$8,769 Mln
Revenue (TTM)
$831 Mln
P/E Ratio
180.3
P/B Ratio
12.4
Div. Yield
0 %
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
8,769 | 14,600 | 11,611 | 11,755 | 10,129 |
Revenue ($ Mln) |
831 | 946 | 5,020 | 331,377 | 432 |
Net Profit ($ Mln) |
54.90 | -570.21 | -199.00 | 28,032.40 | -136.72 |
Net Margin (%) |
6.61 | -60.30 | -3.96 | 8.46 | -31.66 |
RoE (%) |
8.11 | -- | -3.03 | 7.51 | -30.32 |
Price to Earnings |
180.27 | -- | -- | 39.19 | -- |
Price-To-Book |
12.42 | 123.68 | 1.72 | 2.91 | 22.73 |
Income Statement ($ Mln)
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
830.81 | 945.54 | 5,020.00 | 331,377.21 | 431.80 |
|
Cost of Revenue
|
14.09 | 61.34 | 2,380.00 | 167,448.74 | 207.41 |
|
Gross Profit
|
748.43 | 473.81 | 2,050.00 | 190,428.00 | 191.00 |
|
Operating Expenses
|
810.32 | 1,294.12 | 2,178.00 | 134,367.32 | 362.16 |
|
Operating Profit (EBIT)
|
6.41 | -409.91 | 462.00 | 29,561.14 | -137.77 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
26.37 | -578.95 | -166.00 | 35,270.62 | -135.85 |
|
Provision for Tax
|
-35.26 | -4.96 | 33.00 | 7,639.53 | 0.24 |
|
Profit after Tax (Net Income)
|
54.90 | -570.21 | -199.00 | 28,032.40 | -136.72 |
|
Minority Interest
|
0.00 | 11.75 | 0.00 | 401.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 12,099.00 | 0.00 |
Liabilities ($ Mln)
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
705.78 | -1,662.34 | 6,588.00 | 387,871.57 | 445.74 |
|
Minority Interest
|
0.00 | 11.75 | 0.00 | 401.00 | 0.00 |
|
Non-Current Liabilities
|
29.12 | 2,838.05 | 5,121.00 | 30,754.20 | 106.44 |
|
Current Liabilities
|
153.80 | 977.24 | 1,852.00 | 155,168.12 | 120.26 |
|
Total Liabilities
|
836.65 | 936.03 | 13,358.00 | 492,989.00 | 641.86 |
Assets ($ Mln)
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
449.03 | 117.18 | 9,764.00 | 278,119.64 | 351.14 |
|
Current Assets
|
439.68 | 2,044.61 | 3,797.00 | 298,879.23 | 321.30 |
|
Total Assets
|
836.65 | 936.03 | 13,358.00 | 492,989.00 | 641.86 |
|
Total Debt*
|
9.42 | 2,494.05 | 3,918.00 | 72,603.83 | 93.59 |
|
Net Current Assets
|
285.87 | 1,067.37 | 1,945.00 | 143,084.00 | 201.04 |
Cashflow ($ Mln)
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
142.00 | -445.91 | 560.00 | 46,428.00 | -47.63 |
|
Cash Flow from Investing Activities
|
69.76 | -24.49 | -279.00 | -58,077.00 | -24.76 |
|
Cash from Financing Activities
|
-220.37 | 359.29 | -275.00 | 18,911.00 | 28.54 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
14.87 | -159.44 | -2.21 | 16.61 | -13.30 |
|
ROE (%)
|
8.11 | 41.15 | -3.03 | 7.51 | -30.32 |
|
ROA (%)
|
5.52 | -26.19 | -1.30 | 3.93 | -17.95 |
|
EBIT Margin (%)
|
3.17 | -47.10 | 1.61 | 9.79 | -30.84 |
|
Net Margin (%)
|
6.61 | -60.30 | -3.96 | 8.46 | -31.66 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
16.02 | 167.27 | 11.95 | -3.15 | 19.19 |
|
EBIT Growth (%)
|
-79.11 | 34.77 | -90.61 | -59.13 | -57.38 |
|
Net Profit Growth (%)
|
-58.66 | 28.47 | -145.85 | -52.18 | -60.49 |
|
EPS Growth (%)
|
-62.44 | 30.63 | -146.42 | -52.16 | -52.59 |
|
Book Value Growth (%)
|
12.98 | 16.42 | -3.87 | 8.16 | -8.64 |
Valuation Ratios
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
41.86 | -20.69 | -48.47 | 0.19 | -21.89 |
|
Price / Book Value
|
6.44 | -7.27 | 1.72 | 0.03 | 3.60 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
55.67 | -25.47 | 21.77 | 0.00 | -30.81 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | -1.16 | 0.58 | 0.03 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | -0.33 | 0.01 | 0.16 | 0.02 |
|
Current Ratio
|
2.86 | 2.09 | 2.05 | 1.93 | 2.67 |
|
Quick Ratio
|
2.77 | 2.03 | 1.10 | 1.40 | 2.38 |
|
Interest Coverage
|
-- | -3.33 | 0.36 | 8.78 | -- |
Operating Efficiency Ratios
| Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
9.26 | 39.67 | 22.95 | 30.73 | 15.23 |
|
Asset Turnover
|
0.84 | 0.43 | 0.33 | 0.46 | 0.57 |
|
Receivable days
|
28.27 | 52.44 | 70.73 | 115.08 | 44.72 |
|
Inventory Days
|
355.76 | 172.81 | 226.89 | 181.99 | 51.56 |
|
Payable days
|
785.55 | 296.14 | 45.50 | 56.23 | 12.52 |
|
Cash Conversion Cycle
|
-401.52 | -70.89 | 252.12 | 240.84 | 83.76 |